Encyclopédie médico-chirurgicale. Ophtalmologie, Journal Year: 2024, Volume and Issue: 41(3), P. 1 - 15
Published: Sept. 1, 2024
Urology Case Reports, Journal Year: 2024, Volume and Issue: 53, P. 102670 - 102670
Published: Feb. 5, 2024
A 55-year-old woman with dyspnea was diagnosed a 9.5cm left renal clear cell carcinoma and extensive metastatic disease. Initial treatment Sunitinib effective but discontinued due to severe dermatitis. Nivolumab therapy led complete metastasis resolution consequently nephrectomy performed at 12 months. Postoperatively, she developed Vogt-Koyanagi-Harada-like disease, necessitating suspension vision improvement corticosteroids. After 24 disease-free months, new contralateral lesion pulmonary metastases were identified, prompting cabozantinib treatment. This resulted in clinical partial response the first follow-up.
Language: Английский
Citations
2
American Journal of Ophthalmology Case Reports, Journal Year: 2024, Volume and Issue: 36, P. 102025 - 102025
Published: Feb. 18, 2024
Conjunctival melanoma is a rare neoplasm with high rates of recurrence and metastasis. Traditional management includes surgical excision cryotherapy, followed by adjuvant therapy as needed. Immune checkpoint inhibitors, including nivolumab, are targeted treatment option improved survival rates. However, various immune-related adverse effects have been reported these drugs. While systemic granulomatous inflammation documented side effect, it has rarely in the conjunctiva ocular adnexa.
Language: Английский
Citations
1
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 10, 2024
Immune checkpoint inhibitors, which are a type of cancer immunotherapy, have been associated with the development adverse events related to an overactive immune system caused by effect this therapy. It affects wide range organs, including ear and eye. Ophthalmic toxicity inhibitors usually occurs bilaterally. Corneal (mainly dry eye disease) uveitis most commonly reported patterns toxicity. Other involvement include optic neuritis, serous retinal detachment, keratitis, ophthalmoplegia, ocular myasthenia, but not limited them. Potential factors contributing age, previous history disease, type, doses, duration treatment, race. Ototoxicity is also in literature, manifesting as bilateral, symmetrical/asymmetrical hearing loss. Ear presenting fullness, tinnitus, vertigo has mentioned literature. Hearing loss often word/speech recognition. An audiogram shows pattern sensorineural Otitis media be potential cause inhibitor was present more when used along other anti-neoplastic agents. toxicity, presumably results from damage melanocytes ear, presents melanocytotic manifestations, like vitiligo. According some agents (ipilimumab, nivolumab, atezolizumab, pembrolizumab) were toxic effects on combined each other.
Language: Английский
Citations
1
American Journal of Ophthalmology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
Language: Английский
Citations
1
Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2547 - 2547
Published: Nov. 7, 2024
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering significant improvements in patient survival across various malignancies. However, their use is associated with a broad spectrum of immune-related adverse events (irAEs), including those affecting the eye and its surrounding structures, collectively termed ocular irAEs (OirAEs). Although rare, OirAEs (e.g., keratitis, uveitis, retinal vasculitis, etc.) can significantly impact patient's quality life, leading to complications if left untreated. This review provides comprehensive overview ICIs, clinical manifestations, underlying mechanisms, current management strategies. We delve into anterior posterior segment events, highlighting conditions such as dry eye, disorders, well neuro-ophthalmic orbital complications. Furthermore, we discuss challenges diagnosing treating these conditions, particularly given overlap other autoimmune paraneoplastic syndromes. Finally, identify key knowledge gaps suggest future research directions aimed at optimizing while maintaining efficacy therapy. underscores need for increased awareness among clinicians prevent irreversible damage enhance outcomes.
Language: Английский
Citations
1
Ophthalmology and Therapy, Journal Year: 2024, Volume and Issue: 13(7), P. 2061 - 2061
Published: March 11, 2024
We describe a case of cystoid macular oedema associated with combination treatment using STING agonist and ezabenlimab for disseminated melanoma. A 66-year-old male patient presented worsening vision in the right eye, along small accumulation subretinal fluid left eye. The has been undergoing melanoma since 2014. Five months prior to ocular presentation, was enrolled first-in-human trial ezabenlimab. Topical dexamethasone 0.1% drops ketorolac 0.5% prescribed, he continued systemic immunotherapy. After 6 weeks, morphological functional improvement noted; however, persisted. Consequently, immunotherapy temporarily suspended. an additional 4 regressed eye completely resolved In melanoma, emerged as notable side effect worsening. This highlights importance careful monitoring patients receiving this therapy. cGAS–STING pathway is important target future research treating inflammatory conditions.
Language: Английский
Citations
0
Current Neurology and Neuroscience Reports, Journal Year: 2024, Volume and Issue: 24(5), P. 113 - 122
Published: March 18, 2024
Language: Английский
Citations
0
Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Citations
0
Clinics of Oncology, Journal Year: 2024, Volume and Issue: 07(12), P. 01 - 04
Published: July 22, 2024
1.1. Purpose: To report a case of severe sight loss following single infusion pembrolzumab 1.2. Methods: Retrospective 1.3. Results: Ocular adverse events associated with immune checkpoint inhibitors, due to their rarity, remain poorly characterised. Pembrolizumab targets the programmed cell death (PD-1) protein on T cells, circumventing mechanisms by which cancer cells evade body’s adaptive response. date, reports ocular surface disease, neuro-ophthalmic complications, orbitopathy, retinal dysfunction and uveitis have been reported pembrolizumab infusion. We first panuveitis resulting in vision, initial pembrolizumab. 1.4. Conclusion: The serves as heartening reminder need for prompt reporting visual symptoms, recognition immune-related multi-disciplinary approach between oncology ophthalmology patients receiving immunotherapy treatment.
Language: Английский
Citations
0
Deleted Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 30, 2024
Citations
0